Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy
Pediatric Blood & Cancer2014Vol. 61(6), pp. 1013–1016
Citations Over Time
Gábor Ottóffy, Petra Horváth, L Muth, Alexander Sólyom, Miklós Garami, Gábor M. Kovács, Tibor Nyári, Dénes Molnár, Gábor Pauler, István Jankovics
Abstract
Whole-virion, inactivated, adjuvanted vaccine for the pandemic H1N1 Influenza A virus and the seasonal influenza vaccines were found safe and partially immunogenic in children with cancer receiving chemotherapy. The only determinants of responsiveness were lymphocyte count and serum immunoglobulin-G. Only influenza B vaccine elicited significant differences in differences in pre- and post-vaccination seroprotective rates. The response to vaccination for pandemic H1N1 is as effective as other vaccines, however administration of a single vaccine during chemotherapy is more comfortable for pediatric cancer patients.
Related Papers
- → Systems biology of vaccination for seasonal influenza in humans(2011)821 cited
- → Comparison of A(H3N2) Neutralizing Antibody Responses Elicited by 2018–2019 Season Quadrivalent Influenza Vaccines Derived from Eggs, Cells, and Recombinant Hemagglutinin(2020)27 cited
- → Use of MDCK cells for production of live attenuated influenza vaccine(2009)94 cited
- → Effect of the Prior Influenza Vaccination on Serum Antibody Titer Induction by Subsequent Inactivated Influenza Vaccine in the Elderly(1997)1 cited
- → Efficacy of Influenza Vaccine among Geriatric Inpatients(1999)